New York S 10260: Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S10260 Summary:

BILL NOS10260 

&nbsp

SAME ASSAME AS A10521-A

&nbsp

SPONSORWEBB

&nbsp

COSPNSRPARKER, RYAN C

&nbsp

MLTSPNSR

&nbsp

Amd §2500-a, Pub Health L

&nbsp

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Go to top S10260 Actions:

BILL NOS10260 

&nbsp

05/08/2026REFERRED TO HEALTH

Go to topS10260 Committee&nbspVotes:

Go to topS10260 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS10260 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 10260

 IN SENATE

 May 8, 2026
 ___________

 Introduced by Sen. WEBB -- read twice and ordered printed, and when
 printed to be committed to the Committee on Health

 AN ACT to amend the public health law, in relation to newborn screening
 for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. Subdivision 1 of section 2500-a of the public health law is
 2 amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read
 3 as follows:
 4 (l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
 5 (m) Mucopolysaccharidosis type IVA (MPS IVA).
 6 (n) Mucopolysaccharidosis type VI (MPS VI).
 7 (o) Mucopolysaccharidosis type VII (MPS VII).
 8 (p) Fabry.
 9 § 2. Section 2500-a of the public health law is amended by adding a
 10 new subdivision 4 to read as follows:
 11 4. The commissioner shall ensure tests are made available for all
 12 diseases and conditions designated pursuant to paragraphs (l), (m), (n),
 13 (o) and (p) of subdivision one of this section within twelve months of
 14 the effective date of such paragraphs.
 15 § 3. This act shall take effect immediately.

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD15047-03-6

Go to top 

• 

 Sitemap 

 Request Information 

 Directions and Maps